Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

URN to cite this document:: urn:nbn:de:bvb:355-epub-450581
DOI to cite this document:: 10.5283/epub.45058

Werner-Klein, Melanie ; Grujovic, Ana ; Irlbeck, Christoph ; Obradović, Milan ; Hoffmann, Martin ; Koerkel-Qu, Huiqin ; Lu, Xin ; Treitschke, Steffi ; Köstler, Cäcilia ; Botteron, Catherine ; Weidele, Kathrin ; Werno, Christian ; Polzer, Bernhard ; Kirsch, Stefan

; Gužvić, Miodrag ; Warfsmann, Jens ; Honarnejad, Kamran ; Czyz, Zbigniew ; Feliciello, Giancarlo ; Blochberger, Isabell ; Grunewald, Sandra ; Schneider, Elisabeth ; Haunschild, Gundula ; Patwary, Nina ; Guetter, Severin ; Huber, Sandra ; Rack, Brigitte ; Harbeck, Nadia ; Buchholz, Stefan ; Rümmele, Petra ; Heine, Norbert ; Rose-John, Stefan ; Klein, Christoph A.

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(2MB)

Date of publication of this fulltext: 23 Feb 2021 12:56

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Although thousands of breast cancer cells disseminate and home to bone marrow until primary surgery, usually less than a handful will succeed in establishing manifest metastases months to years later. To identify signals that support survival or outgrowth in patients, we profile rare bone marrow-derived disseminated cancer cells (DCCs) long before manifestation of metastasis and identify ...